AZD6140

Bibliography

• YUSUF S, ZHAO F, MEHTA SR et al.; CLOPIDOGREL IN UNSTABLE ANGINA TO PREVENT RECURRENT EVENTS TRIAL INVESTIGATORS: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345:494-502.
   PubMed Web of Science ®Google Scholar
• STEINHUBL SR, BERGER PB, MANN JT III et al.; CREDO INVESTIGATORS: CLOPIDOGREL FOR THE REDUCTION OF EVENTS DURING OBSERVATION. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 288:2411-2420.
   PubMed Web of Science ®Google Scholar
• MEHTA SR, YUSUF S, PETERS RJ et al.: Clopidogrel in Unstable Angina to Prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358:527-533.
   PubMed Web of Science ®Google Scholar
• BERTRAND ME, RUPPRECHT HJ, URBAN P, GERSHLICK AH; CLASSICS INVESTIGATORS: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative study (CLASSICS). Circulation (2000) 102:624-629.
   PubMed Web of Science ®Google Scholar
• GURBEL PA, BLIDEN KP, HIATT BL, O'CONNOR CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 107:2908-2913.
   PubMed Web of Science ®Google Scholar
• GURBEL PA, BLIDEN KP, HAYES KM, YOHO JA, HERZOG WR, TANTRY US: The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol. (2005) 45:1392-1396.
   PubMed Web of Science ®Google Scholar
• MATETZKY S, SHENKMAN B, GUETTA V et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 109:3171-3175.
   PubMed Web of Science ®Google Scholar
• GURBEL PA, BLIDEN KP, SAMARA W et al.: Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J. Am. Coll. Cardiol. (2005) 46:1827-1832.
   PubMed Web of Science ®Google Scholar
• AJZENBERG N, AUBRY P, HUISSE MG et al.: Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J. Am. Coll. Cardiol. (2005) 45:1753-1756.
   PubMed Web of Science ®Google Scholar
• BARRAGAN P, BOUVIER JL, ROQUEBERT PO et al.: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc. Interv. (2003) 59:295-302.
   PubMed Web of Science ®Google Scholar
• GURBEL PA, BLIDEN KP, GUYER K et al.: Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J. Am. Coll. Cardiol. (2005) 46:1820-1826.
   PubMed Web of Science ®Google Scholar
• BLIDEN KP, TANTRY U, ZAMAN K et al.: High platelet reactivity is a risk factor for post-discharge ischemic complications following elective coronary stenting. J. Am. Coll. Cardiol. (2005) 45:33A.
   Google Scholar
• CUISSET T, FRERE C, QUILICI J et al.: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost. (2006) 4:542-549.
   PubMed Web of Science ®Google Scholar
• GURBEL PA, TANTRY US: Drug insight: clopidogrel nonresponsiveness. Nat. Clin. Pract. Cardiovasc. Med. (2006) 3:387-395.
   PubMedGoogle Scholar
• TANTRY US, BLIDEN KP, GURBEL PA: Resistance to antiplatelet drugs: current status and future research. Expert Opin. Pharmacother. (2005) 6(12):2027-2045.
   PubMed Web of Science ®Google Scholar
• HUSTED S, EMANUELSSON H, HEPTINSTALL S, SANDSET PM, WICKENS M, PETERS G: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. (2006) 27:1038-1047.
   PubMed Web of Science ®Google Scholar
• VAN GIEZEN JJ, HUMPHRIES RG: Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. (2005) 31:195-204.
   PubMed Web of Science ®Google Scholar
• PETERS G, ROBBIE G: Single dose pharmacokinetics and pharmacodynamics of AZD6140. Haematologica (2004) 89(Suppl. 7):14-15.
   Google Scholar
• PETERS GR, BUTLER KA, WINTER HR, MITCHELL PD: Multiple-doe pharmacokinetics (PK) and pharmacodynamics (PD) of the oral reversible, orally active ADP receptor antagonist AZD6140. World Congress of Cardiology, Barcelona, Spain (2006):P4556.
   Google Scholar
• CANNON CP, MAHAFFEY K, HARRINGTON RA et al.: Clinical outcomes with AZD6140, an oral reversible ADP receptor antagonist, compared with clopidogrel (CLOP) in patients with acute coronary syndromes (ACS). J. Am. Coll. Cardiol. (2006) 47:199A.
   Web of Science ®Google Scholar
• GURBEL PA, BLIDEN KP, ZAMAN KA, YOHO JA, HAYES KM, TANTRY US: Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation (2005) 111:1153-1159.
   PubMed Web of Science ®Google Scholar
• EMANUELSSON H, MAHAFFEY K, HARRINGTON RA: Can greater inhibition of platelet aggregation be tolerated? evaluation of the bleeding risk of AZD6140 compared with clopidogrel (CLOP) in patients with acute coronary syndromes (ACS). J. Am. Coll. Cardiol. (2006) 47:212A.
   PubMedGoogle Scholar
• HUSTED S, STOREY RF, HARRINGTON FA et al.: The effects of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel on biochemical markers in patients with acute coronary syndromes (ACS). J. Am. Coll. Cardiol. (2006) 47:200A.
   Google Scholar
• STOREY RF, HUSTED S, HARRINGTON RA et al.: AZD6410 yields greater inhibition of platelet aggregation than clopidogrel in patients with acute coronory syndromes without previous clopidogrel treatment. J. Am. Coll. Cardiol. (2006) 47:204A.
   Google Scholar